Jeff Lagasse is Associate Editor at Healthcare Finance.
Machine learning, AI, telemedicine and other technologies will pose data security risks, says Dr. John Halamka
By Jeff Lagasse 01:45 pm December 10, 2019
While the shift is necessary, the transition period will likely see hackers targeting newly vulnerable information, said Halamka.
By Jeff Lagasse 04:35 pm December 09, 2019
Risk can have a profound impact on the financial health of any organization, where sensitive information is often hosted on outside servers.
Healthcare data breaches will cost industry $4 billion by year's end, and 2020 is poised to be worse
By Jeff Lagasse 02:54 pm November 04, 2019
Providers continue to be the most targeted organizations for industry cybersecurity breaches, with nearly 4 out of 5 breaches.
By Jeff Lagasse 11:35 am October 29, 2019
Wasteful spending is an increasingly thorny problem in healthcare, especially with the industry comprising an ever-larger portion of GDP.
Financial incentives plus information decrease patient preference for potentially wasteful diagnostic testing
By Jeff Lagasse 07:07 am October 29, 2019
Discussing benefits and risks of low-value diagnostic testing via head CT scan with patients can reduce the prevalence of such testing.
By Jeff Lagasse 07:07 am October 21, 2019
Despite this cost increase, 95% of employers are very confident their organization will continue to sponsor healthcare benefits to active employees.
By Jeff Lagasse 04:46 pm October 17, 2019
The FDA is also approving greater numbers of complex generic drugs, which are more difficult to replicate and traditionally lack competition.
By Jeff Lagasse 03:54 pm October 16, 2019
A tiny fraction of healthcare executives, 5%, said clinical integration is their supply chain't top priority.
By Jeff Lagasse 03:24 pm October 16, 2019
On average, physician-led ACOs produced almost 7 times the amount of Medicare savings per beneficiary than hospital-led ACOs.
By Jeff Lagasse 11:39 am October 15, 2019
The anticipated savings would increase in a scenario in which biosimilars made up a larger portion of the total market share.